Table 2.
Novel immunotherapies in clinical trials in chronic HBV infection.
| Drug Family | Drug Name | Trial Number | Phase | Status | Sponsor |
|---|---|---|---|---|---|
| Therapeutic vaccines | JNJ-64300535 | NCT03463369 | 1 | Recruiting | Janssen Sciences |
| FP-02.2 | NCT02496897 | 1 | Completed | Altimmune, Inc. | |
| DV-601 | NCT01023230 | 1 | Completed | Dynavax Technologies Co | |
| INO-1800 with orwWithout INO-9112 | NCT02431312 | 1 | Completed | Inovio Pharmaceuticals | |
| Multiple molecules | NCT03866187 | 1 | Recruiting | GlaxoSmithKline | |
| HBV0003 | NCT03038802 | 1 | Not yet recruiting | Vaxine Pty Ltd. | |
| TG1050 | NCT04168333 | 1 | Completed | Tasly Tianjin Biopharmaceutical | |
| NCT02428400 | 1 | Completed | Transgene | ||
| GS4774 | NCT01943799 | 2 | Completed | Gilead Sciences | |
| NCT02174276 | 2 | Completed | Gilead Sciences | ||
| T101 (therapeutic HB Adenovirus) | NCT04168333 | 1 | Completed | Tasly Tianjin Biopharmaceutical | |
| ABX203 | NCT02249988 | 3 | Completed | Abivax S.A. | |
| Toll-like receptors agonists | GS9688 (Selgantolimod) | NCT03491553 | 2 | Active | Gilead Sciences |
| NCT03615066 | 2 | Active | Gilead Sciences | ||
| GS-9620 (Vesatolimod) | NCT02579382 | 2 | Completed | Gilead Sciences | |
| NCT02166047 | 2 | Completed | Gilead Sciences | ||
| RO7020531 (also nknown as RG7854) | NCT02956850 | 1 | Recruiting | Hoffmann-La Roche | |
| TQ-A3334 | NCT04180150 | 2 | Recruiting | Chia Tai Tianqing | |
| RO6864018 (also known as RG7795) | NCT02391805 | 2 | Completed | Hoffmann-La Roche | |
| Apoptosis inducer | APG-1387 | NCT03585322 | 1 | Active, not recruiting | Ascentage Pharma |
| RIG-I agonists | Inarigivir Soproxil (GS-9992) | NCT03434353 | 2 | Active, not recruiting | Gilead Sciences |
| NCT04059198 | 2 | Active, not recruiting | Gilead Sciences | ||
| SB-9200 | NCT02751996 | 2 | Completed | Spring Bank Pharmaceuticals | |
| Ciclophilin inhibitor | CRV-31 | NCT03596697 | 1 | Active, not recruiting | ContraVir Pharmaceuticals |
| Monoclonal anti-HBsAg antibody | GC1102 | NCT03801798 | 2 | Active, not recruiting | Green Cross Corporation |
| Unknown mechanism of action | RO7239958 (also known as RG6217) | NCT03762681 | 1 | Recruiting | Hoffmann-La Roche |
| Anti-programmed cell death-1 (PD-1) humanized monoclonal antibody | HLX10 | NCT04133259 | 2 | Not yet recruiting | Henlix, Inc. |
| Cemiplimab | NCT04046107 | 2 | Recruiting | National Institute of Allergy Inf Dis |
Note: No preclinical data are included. Only clinical trials completed within the last 2 years are included. Data are drawn from ClinicalTrials.gov.